MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, TOVX has $30,836K in assets. $24,098K in debts. $7,528K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
90.00%
Cash Ratio
68.42%
Debt to Asset Ratio
78.15%
Assets Breakdown
    • In-process research and developm...
    • Cash and cash equivalents
    • Tax credit receivable
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Non-current contingent considera...
    • Others

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Balance Sheets
2025-09-30
2025-06-30
Cash and cash equivalents
7,528 12,120
Tax credit receivable
1,721 1,722
Prepaid expenses and other current assets
654 901
Total current assets
9,903 14,743
Property and equipment, net
249 258
Restricted cash
46 46
Right of use asset
942 1,077
In-process research and development
19,614 19,624
Deposits and other assets
82 82
Total assets
30,836 35,830
Accounts payable
795 607
Accrued expenses
7,685 9,017
Accrued employee benefits
747 759
Deferred research and development tax credit-current portion
1,101 1,343
Loans payable-current
57 56
Operating lease liability-current portion
618 612
Total current liabilities
11,003 12,394
Non-current contingent consideration
10,793 10,160
Loan payable - non-current
1,654 1,639
Non-current deferred research and development tax credit
215 430
Non-current operating lease liability
433 584
Preferred stock 10,000,000 authorized none issued or outstanding at june 30, 2025 and december 31, 2024
-0
Total liabilities
24,098 25,207
Common stock, 0.001 par value 350,000,000 shares authorized, 10,333,572 issued and 10,304,762 outstanding at september 30, 2025 and 2,811,259 issued and 2,782,449 outstanding at december 31, 2024
9 8
Additional paid-in capital
362,968 362,463
Treasury stock at cost, 28,809 shares at september 30, 2025 and at december 31, 2024
288 288
Accumulated other comprehensive income (loss)
763 793
Accumulated deficit
-356,714 -352,353
Total stockholders' equity
6,738 10,623
Total liabilities and stockholders' equity
30,836 35,830
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Prepaid expenses andother current assets$654K Tax creditreceivable$1,721K Cash and cashequivalents$7,528K Deposits and other assets$82K In-process research anddevelopment$19,614K Right of use asset$942K Restricted cash$46K Property and equipment,net$249K Total current assets$9,903K Total assets$30,836K Total liabilities andstockholders' equity$30,836K Total stockholders'equity$6,738K Total liabilities$24,098K Accumulated deficit-$356,714K Treasury stock at cost,28,809 shares at...$288K Accumulated othercomprehensive income (loss)$763K Additional paid-in capital$362,968K Non-current operating leaseliability$433K Non-current deferredresearch and development...$215K Loan payable -non-current$1,654K Non-current contingentconsideration$10,793K Total currentliabilities$11,003K Common stock, 0.001 parvalue 350,000,000...$9K Operating leaseliability-current portion$618K Loanspayable-current$57K Deferred research anddevelopment tax...$1,101K Accrued employeebenefits$747K Accrued expenses$7,685K Accounts payable$795K

Theriva Biologics, Inc. (TOVX)

Theriva Biologics, Inc. (TOVX)